Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus.

Ascher-Svanum H, Lage MJ, Perez-Nieves M, Reaney MD, Lorraine J, Rodriguez A, Treglia M.

Diabetes Ther. 2014 Jun;5(1):225-42. doi: 10.1007/s13300-014-0065-z. Epub 2014 Apr 30.

PMID:
24782063
[PubMed]
Free PMC Article
2.

Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia.

Detke HC, Weiden PJ, Llorca PM, Choukour M, Watson SB, Brunner E, Ascher-Svanum H.

J Clin Psychopharmacol. 2014 Aug;34(4):426-34. doi: 10.1097/JCP.0000000000000140.

PMID:
24781441
[PubMed - in process]
3.

Characteristics of patients misdiagnosed with Alzheimer's disease and their medication use: an analysis of the NACC-UDS database.

Gaugler JE, Ascher-Svanum H, Roth DL, Fafowora T, Siderowf A, Beach TG.

BMC Geriatr. 2013 Dec 19;13:137. doi: 10.1186/1471-2318-13-137.

PMID:
24354549
[PubMed - in process]
Free PMC Article
4.

The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial.

Chen L, Johnston JA, Kinon BJ, Stauffer V, Succop P, Marques TR, Ascher-Svanum H.

BMC Psychiatry. 2013 Nov 28;13:320. doi: 10.1186/1471-244X-13-320.

PMID:
24283222
[PubMed - indexed for MEDLINE]
Free Article
5.

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study.

Ascher-Svanum H, Novick D, Haro JM, Bertsch J, McDonnell D, Detke H.

BMC Psychiatry. 2013 Sep 16;13:224. doi: 10.1186/1471-244X-13-224.

PMID:
24041270
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy.

Montgomery W, Liu L, Stensland MD, Xue HB, Treuer T, Ascher-Svanum H.

Clinicoecon Outcomes Res. 2013 Aug 14;5:407-18. doi: 10.2147/CEOR.S44325. eCollection 2013.

PMID:
23983478
[PubMed]
Free PMC Article
7.

Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia.

Chen L, Ascher-Svanum H, Lawson A, Stauffer VL, Nyhuis A, Haynes V, Schuh K, Kinon BJ.

Neuropsychiatr Dis Treat. 2013;9:815-22. doi: 10.2147/NDT.S43574. Epub 2013 Jun 14.

PMID:
23807848
[PubMed]
Free PMC Article
8.

Early Perception of Medication Benefit Predicts Subsequent Antipsychotic Response in Schizophrenia.

Ascher-Svanum H, Weiden P, Nyhuis A, Faries D, Stauffer V, Kollack-Walker S, Kinon B.

Clin Schizophr Relat Psychoses. 2013 Feb 27:1-28. [Epub ahead of print]

PMID:
23446198
[PubMed - as supplied by publisher]
9.

Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being.

Naber D, Kollack-Walker S, Chen J, Stauffer VL, Kinon BJ, Case M, Ascher-Svanum H, Kapur S, Kane JM.

Pharmacopsychiatry. 2013 May;46(3):114-9. doi: 10.1055/s-0032-1331703. Epub 2013 Jan 4.

PMID:
23293013
[PubMed - indexed for MEDLINE]
10.

Comparing symptom response among antipsychotic medications in CATIE.

Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH.

J Clin Psychopharmacol. 2013 Feb;33(1):123-6. doi: 10.1097/01.jcp.0000426178.43831.ed. No abstract available.

PMID:
23288232
[PubMed - indexed for MEDLINE]
11.

Comparing Symptom Response Among Antipsychotic Medications in CATIE.

Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH.

J Clin Psychopharmacol. 2012 Dec 28. [Epub ahead of print] No abstract available.

PMID:
23277269
[PubMed - as supplied by publisher]
12.

Empirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia.

Ascher-Svanum H, Novick D, Haro JM, Aguado J, Cui Z.

Qual Life Res. 2013 Oct;22(8):2085-94. doi: 10.1007/s11136-012-0335-z. Epub 2012 Dec 14.

PMID:
23239123
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study.

Haynes VS, Zhu B, Stauffer VL, Kinon BJ, Stensland MD, Xu L, Ascher-Svanum H.

BMC Psychiatry. 2012 Dec 5;12:222. doi: 10.1186/1471-244X-12-222.

PMID:
23216976
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.

Faries D, Ascher-Svanum H, Phillips G, Nyhuis AW, Sugihara T, Stauffer V, Kinon BJ.

BMC Med Res Methodol. 2012 Sep 13;12:142. doi: 10.1186/1471-2288-12-142.

PMID:
22974273
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation.

Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, Awad AG, Keefe RS, Naber D.

Patient Prefer Adherence. 2012;6:521-32. doi: 10.2147/PPA.S25635. Epub 2012 Jul 13.

PMID:
22879738
[PubMed]
Free PMC Article
16.

Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.

Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, George Awad A, Keefe RS, Naber D.

Psychiatry Res. 2012 Dec 30;200(2-3):835-42. doi: 10.1016/j.psychres.2012.05.005. Epub 2012 Jul 28.

PMID:
22841345
[PubMed - indexed for MEDLINE]
17.

Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.

Novick D, Ascher-Svanum H, Brugnoli R, Bertsch J, Hong J, Haro JM.

J Nerv Ment Dis. 2012 Jul;200(7):637-43. doi: 10.1097/NMD.0b013e31825bfd95.

PMID:
22759944
[PubMed - indexed for MEDLINE]
18.

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis.

Ye W, Ascher-Svanum H, Tanji Y, Flynn JA, Takahashi M, Conley RR.

Neuropsychiatr Dis Treat. 2012;8:259-66. doi: 10.2147/NDT.S25662. Epub 2012 Jun 18.

PMID:
22745559
[PubMed]
Free PMC Article
19.

Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.

Soares-Weiser K, B├ęchard-Evans L, Lawson AH, Davis J, Ascher-Svanum H.

Eur Neuropsychopharmacol. 2013 Feb;23(2):118-25. doi: 10.1016/j.euroneuro.2012.05.001. Epub 2012 May 26. Review.

PMID:
22633617
[PubMed - indexed for MEDLINE]
20.

Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.

Ye W, Fujikoshi S, Nakahara N, Takahashi M, Ascher-Svanum H, Ohmori T.

Psychiatry Clin Neurosci. 2012 Jun;66(4):313-21. doi: 10.1111/j.1440-1819.2012.02351.x.

PMID:
22624736
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk